157 related articles for article (PubMed ID: 38387107)
1. Who benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-dimensional model for candidate selection.
Jiang MQ; Qian LQ; Shen YJ; Fu YY; Feng W; Ding ZP; Han YC; Fu XL
Neoplasia; 2024 Apr; 50():100979. PubMed ID: 38387107
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance and survival benefits of postoperative adjuvant chemotherapy in patients with stage IA lung adenocarcinoma with non-predominant micropapillary components.
Li R; Qiu J; Li Z; Li H; Tang Z; Yu W; Tian H; Sun Z
World J Surg Oncol; 2024 Jan; 22(1):32. PubMed ID: 38273367
[TBL] [Abstract][Full Text] [Related]
3. Impact of surgery and adjuvant chemotherapy on the survival of stage I lung adenocarcinoma patients with tumor spread through air spaces.
Lv Y; Li S; Liu Z; Ren Z; Zhao J; Tao G; Zheng Z; Han Y; Ye B
Lung Cancer; 2023 Mar; 177():51-58. PubMed ID: 36736075
[TBL] [Abstract][Full Text] [Related]
4. The IASLC Proposed Grading System Accurately Predicts Prognosis and Mediastinal Nodal Metastasis in Patients With Clinical Stage I Lung Adenocarcinoma.
Xu L; Su H; Hou L; Wang F; Xie H; She Y; Gao J; Zhao S; Dai C; Xie D; Zhu Y; Wu C; Zhao D; Chen C;
Am J Surg Pathol; 2022 Dec; 46(12):1633-1641. PubMed ID: 36224092
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification in stage IB lung adenocarcinoma.
Xu CH; Wang W; Wei Y; Hu HD; Zou J; Yan J; Yu LK; Yang RS; Wang Y
Eur J Surg Oncol; 2015 Oct; 41(10):1430-6. PubMed ID: 26123994
[TBL] [Abstract][Full Text] [Related]
6. Validation Study of New IASLC Histology Grading System in Stage I Non-Mucinous Adenocarcinoma Comparing With Minimally Invasive Adenocarcinoma.
Woo W; Cha YJ; Kim BJ; Moon DH; Lee S
Clin Lung Cancer; 2022 Nov; 23(7):e435-e442. PubMed ID: 35945128
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy in patients with recurrence after completely resected stage IB lung adenocarcinoma: Propensity-matched analysis in a cohort of 147 recurrences.
Xu F; Chen HC; Xu H; Li J; Hao X; Xing P; Ying J; Wang Y
Thorac Cancer; 2022 Nov; 13(22):3105-3113. PubMed ID: 36104006
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of the new IASLC/ATS/ERS classification of clinical stage IA lung adenocarcinoma.
Murakami S; Ito H; Tsubokawa N; Mimae T; Sasada S; Yoshiya T; Miyata Y; Yokose T; Okada M; Nakayama H
Lung Cancer; 2015 Nov; 90(2):199-204. PubMed ID: 26341957
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of resected invasive mucinous adenocarcinoma compared with the IASLC histologic grading system for invasive nonmucinous adenocarcinoma: Surgical database study in the TKIs era in Korea.
Woo W; Yang YH; Cha YJ; Moon DH; Shim HS; Cho A; Kim BJ; Kim HE; Park BJ; Lee JG; Kim DJ; Paik HC; Lee S; Lee CY
Thorac Cancer; 2022 Dec; 13(23):3310-3321. PubMed ID: 36345148
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of pattern-based grading system by the new IASLC/ATS/ERS classification in Asian patients with stage I lung adenocarcinoma.
Zhao ZR; Xi SY; Li W; Situ DR; Chen KM; Yang H; Su XD; Lin YB; Long H
Lung Cancer; 2015 Dec; 90(3):604-9. PubMed ID: 26547801
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic characteristics and prognostic impact of atypical EGFR mutations in completely resected lung adenocarcinoma.
She Y; Li S; Deng J; Ren Y; Zhao M; Zhong Y; He Y; Chen Q; Zhao D; Zhu Y; Hou L; Wu C; Xie D; Chen C
Eur J Cancer; 2022 Dec; 177():53-62. PubMed ID: 36323053
[TBL] [Abstract][Full Text] [Related]
12. EGFR mutation impacts recurrence in high-risk early-stage lung adenocarcinoma in the IASLC grading system.
Nomura K; Aokage K; Kaminuma Y; Nakai T; Wakabayashi M; Ikeno T; Koike Y; Taki T; Miyoshi T; Tane K; Samejima J; Ishii G; Tsuboi M
Int J Clin Oncol; 2024 Mar; 29(3):248-257. PubMed ID: 38319510
[TBL] [Abstract][Full Text] [Related]
13. Real-world efficacy of adjuvant therapy for totally resected stage I lung adenocarcinoma patients with pathological high-risk factors: propensity score analysis.
Zhao K; Yang L; Liu L; Wang G; Zhang J; Gao X; Guo C; Huang C; Chen Y; Li S
BMC Surg; 2024 May; 24(1):140. PubMed ID: 38720305
[TBL] [Abstract][Full Text] [Related]
14. Application of Lepidic Component Predominance to Adjuvant Chemotherapy with Oral Fluoropyrimidines for Stage I Lung Adenocarcinoma.
Sasada S; Miyata Y; Mimae T; Tsutani Y; Mimura T; Okada M
Clin Lung Cancer; 2016 Sep; 17(5):433-440.e1. PubMed ID: 26725850
[TBL] [Abstract][Full Text] [Related]
15. Validation of the novel International Association for the Study of Lung Cancer grading system and prognostic value of filigree micropapillary and discohesive growth pattern in invasive pulmonary adenocarcinoma.
Zhang Y; Zhang Y; Hu Y; Zhang S; Zhu M; Hu B; Guo X; Lu J; Zhang Y
Lung Cancer; 2023 Jan; 175():79-87. PubMed ID: 36481678
[TBL] [Abstract][Full Text] [Related]
16. The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma.
Tsutani Y; Miyata Y; Mimae T; Kushitani K; Takeshima Y; Yoshimura M; Okada M
J Thorac Cardiovasc Surg; 2013 Sep; 146(3):580-5. PubMed ID: 23778085
[TBL] [Abstract][Full Text] [Related]
17. A pretreatment prediction model of grade 3 tumors classed by the IASLC grading system in lung adenocarcinoma.
Wang K; Liu X; Ding Y; Sun S; Li J; Geng H; Xu M; Wang M; Li X; Sun D
BMC Pulm Med; 2023 Oct; 23(1):377. PubMed ID: 37805451
[TBL] [Abstract][Full Text] [Related]
18. Survival benefit of adjuvant chemotherapy after resection of Stage I lung adenocarcinoma containing micropapillary components.
Li Y; Zhao J; Zhao Y; Li R; Dong X; Yao X; Xia Z; Xu Y; Li Y
Cancer Med; 2024 Feb; 13(3):e7030. PubMed ID: 38400663
[TBL] [Abstract][Full Text] [Related]
19. High-grade tumor classified by new system is a prognostic predictor in resected lung adenocarcinoma.
Yoshida C; Yokomise H; Ibuki E; Go T; Haba R; Kadota K
Gen Thorac Cardiovasc Surg; 2022 May; 70(5):455-462. PubMed ID: 35050467
[TBL] [Abstract][Full Text] [Related]
20. Different prognostic role of EGFR mutation according to the IASLC histological grade in patients with resected early-stage lung adenocarcinoma.
Hong TH; Hwang S; Choi YL; Lee G; Park S; Ahn MJ; Lee Y; Jeon YJ; Lee J; Shin S; Park SY; Cho JH; Choi YS; Kim J; Shim YM; Cho J; Kim HK
Histopathology; 2023 Aug; 83(2):168-177. PubMed ID: 36849852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
